Meeder Asset Management Inc Affimed N.V. Transaction History

Meeder Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$5.37 - $7.07 $44,807 - $58,992	-8,344 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$7.78 - $11.4 $64,916 - $95,121	8,344 New	8,344 $71,000
Q4 2020 Feb 09, 2021	SELL	$3.16 - $7.03 $50,187 - $111,650	-15,882 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$3.26 - $4.73 $404 - $586	-124 Reduced 0.77%	15,882 $54,000
Q2 2020 Aug 11, 2020	BUY	$1.58 - $4.63 $579 - $1,699	367 Added 2.35%	16,006 $73,000
Q1 2020 May 15, 2020	SELL	$1.44 - $3.02 $12,540 - $26,301	-8,709 Reduced 35.77%	15,639 $26,000
Q4 2019 Feb 13, 2020	BUY	$2.25 - $3.07 $18,096 - $24,692	8,043 Added 49.33%	24,348 $65,000
Q3 2019 Oct 17, 2019	BUY	$2.67 - $3.65 $43,534 - $59,513	16,305 New	16,305 $47,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.